Aldeyra Therapeutics Stock Soars 11.27% Post-FDA Rejection

Aldeyra Therapeutics' stock surged by 11.27% in pre-market trading on April 4, 2025, marking a significant rebound after recent setbacks.

Aldeyra Therapeutics experienced a substantial decline in its stock price following the U.S. Food and Drug Administration's (FDA) rejection of its key drug, reproxalap, for the treatment of dry eye disease. The company's stock plummeted by approximately 74% in premarket trading on Thursday, reflecting investor disappointment with the regulatory decision.

Analysts, however, maintain an optimistic outlook for Aldeyra Therapeutics, citing the company's ongoing research and development efforts. Despite the setback, the average price target for the stock remains positive, indicating confidence in the company's long-term prospects.

The FDA's denial of reproxalap has prompted Aldeyra Therapeutics to seek additional clinical trials to address the regulatory concerns. The company is expected to provide further updates on its plans and strategies to advance its pipeline of therapies.